New Blood-Based injection could beat PRP for knee pain

NCT ID NCT06932614

Recruiting now Symptom relief Sponsor: Tri-Service General Hospital Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This study tests whether a new, concentrated version of a patient's own blood platelets (called self-repair factor) works better than standard platelet-rich plasma (PRP) injections for knee osteoarthritis. 90 adults with mild to moderate knee arthritis will receive either the new factor, PRP, or a placebo. The goal is to see which treatment best reduces pain and improves knee function over six months.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Lyophilized self growth factor (a concentrated form of the patient's own blood platelets)
What this could lead to: If it works, this could offer a more effective injection treatment for knee osteoarthritis pain and stiffness, potentially better than current PRP therapy.
What could go wrong: This is a small, early-stage trial with only 90 people. The new treatment may not prove better than PRP or placebo, and individual results vary.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for KNEE OSTEOARTHRITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

osteoarthritis, knee

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

KNEE OSTEOARTHRITIS PRP INJECTION

Contacts and locations

Locations

No. 325, Sec. 2, Chenggong Rd., Neihu Dist.
RECRUITING

Taipei, 114, Taiwan

More trials for these conditions

Other studies related to the condition(s) this trial covers.